3-rx.comCustomer Support
HomeAbout UsFAQContactHelp
News Center
Health Centers
Medical Encyclopedia
Drugs & Medications
Diseases & Conditions
Medical Symptoms
Med. Tests & Exams
Surgery & Procedures
Injuries & Wounds
Diet & Nutrition
Special Topics

\"$alt_text\"');"); } else { echo"\"$alt_text\""; } ?>

Join our Mailing List


You are here : 3-RX.com > Home > Cancer - Prostate Cancer -

Green tea may slow prostate tumor growth

Cancer • • Prostate CancerJun 24, 09

Antioxidant compounds in green tea may help slow the growth and progression of prostate cancer, a preliminary study suggests.

Researchers found that among 26 men with prostate cancer, short-term treatment with the green tea compound epigallocatechin-3-gallate (EGCG) lowered the patients’ blood levels of several proteins linked to prostate cancer progression.

EGCG is the main polyphenol in green tea; polyphenols are antioxidant compounds that, research suggests, may help prevent the cell damage that promotes cancer development and progression.

The current study, which appears in the journal Cancer Prevention Research, does not prove that green tea compounds arrest prostate tumors’ spread.

But it does suggest that EGCG should be studied in larger clinical trials as a potential additional therapy for the disease, according to Dr. James R. Cardelli and colleagues at Louisiana State University Health Sciences Center in Shreveport.

A recent clinical trial in Italy found that men with a pre-cancerous condition called high-grade prostate intraepithelial neoplasia were less likely to develop prostate cancer over one year when they consumed green tea polyphenols.

“These studies are just the beginning and a lot of work remains to be done, however, we think that the use of tea polyphenols alone or in combination with other compounds currently used for cancer therapy should be explored as an approach to prevent cancer progression and recurrence,” Cardelli said in prepared statement from the American Association for Cancer Research.

The study included 26 men recently diagnosed with prostate cancer who were scheduled to have surgery to remove the tumor. Cardelli’s team had all of the patients consume four EGCG-containing capsules every day, up until the day before their surgery—typically for about one month.

The daily EGCG dose was equivalent to about a dozen cups of green tea.

Overall, the researchers found, the men’s levels of several blood proteins—including hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and prostate-specific antigen (PSA)—fell during the study period.

HGF and VEGF are both thought to play a role in cancer cells’ growth and spread. PSA, a protein produced by the prostate gland, tends to rise when prostate cancer develops or recurs.

The findings, according to the researchers, lay the groundwork for further randomized, placebo-controlled trials—the “gold standard” in medical research, where patients are randomly assigned to take the study drug or an inactive substance for comparison.

Pharmaceutical company Polyphenon Pharma supplied the EGCG capsules used in the study. None of the researchers involved in the study reports any financial interest in the product.

SOURCE: Cancer Prevention Research, July 2009.

Print Version
comments powered by Disqus

  New biomarkers may influence drug design and alternative treatments of cancer, study shows
  Metabolic profiles distinguish early stage ovarian cancer with unprecedented accuracy
  Moffitt researchers develop first genetic test to predict tumor sensitivity to radiation therapy
  New drug for neuroblastoma shows promise in phase I study
  Experimental treatment sends deadly leukemia into remission
  Study could reduce unnecessary cancer screening
  UA researchers discover component of cinnamon prevents colorectal cancer in mice
  Profiling approach to enable right lung cancer treatment match
  Fat grafting technique improves results of breast augmentation
  Germline TP53 mutations in patients with early-onset colorectal cancer
  Clinical trial suggests combination therapy is best for low-grade brain tumors
  UW research shows sensor technology may help improve accuracy of clinical breast exams


Home | About Us | FAQ | Contact | Advertising Policy | Privacy Policy | Bookmark Site